PDF(Pubmed)
Abstract：
Human induced pluripotent stem cells (iPSCs) hold great promise for personalized medicine, as they can be differentiated into specific cell types, especially mesenchymal stem cells (MSCs). Therefore, our study sought to assess the feasibility of deriving MSCs from teratomas generated from human iPSCs. Teratomas serve as a model to mimic multilineage human development, thus enriching specific somatic progenitors and stem cells. Here, we discovered a small, condensed mass of MSCs within iPSC-generated teratomas. Afterward, we successfully isolated MSCs from this condensed mass, which was a byproduct of teratoma development. To evaluate the characteristics and cell behaviors of iPSC-derived MSCs (iPSC-MSCs), we conducted comprehensive assessments using qPCR, immunophenotype analysis, and cell proliferation-related assays. Remarkably, iPSC-MSCs exhibited an immunophenotype resembling that of conventional MSCs, and they displayed robust proliferative capabilities, similar to those of higher pluripotent stem cell-derived MSCs. Furthermore, iPSC-MSCs demonstrated the ability to differentiate into multiple lineages in vitro. Finally, we evaluated the therapeutic potential of iPSC-MSCs using an osteochondral defect model. Our findings demonstrated that teratomas are a promising source for the isolation of condensed MSCs. More importantly, our results suggest that iPSC-MSCs derived from teratomas possess the capacity for tissue regeneration, highlighting their promise for future therapeutic applications.
摘要：
人类诱导多能干细胞（iPSCs）在个性化医疗中具有广阔的前景，因为它们可以分化为特定的细胞类型，特别是间充质干细胞（MSCs）。因此,我们的研究旨在评估从人类iPSCs产生的畸胎瘤中获得MSCs的可行性。畸胎瘤作为模拟多谱系人类发育的模型，从而富集特定的体细胞祖细胞和干细胞。这里,我们发现了一个小的，MSCs在iPSC产生的畸胎瘤内的凝聚质量。之后,我们成功地从这个凝聚的物质中分离出了MSCs，这是畸胎瘤发展的副产品。评价iPSC来源的MSCs(iPSC-MSCs)的特性和细胞行为,我们使用qPCR进行了全面评估，免疫表型分析,和细胞增殖相关的测定。值得注意的是,iPSC-MSCs表现出类似于常规MSCs的免疫表型，它们表现出强大的增殖能力，与更高的多能干细胞来源的MSCs相似。此外，iPSC-MSC在体外表现出分化为多个谱系的能力。最后,我们使用骨软骨缺损模型评估了iPSC-MSCs的治疗潜力.我们的发现表明畸胎瘤是分离浓缩MSCs的有希望的来源。更重要的是,我们的结果表明，来自畸胎瘤的iPSC-MSCs具有组织再生能力，强调他们对未来治疗应用的承诺。
